Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Core Insights - Precision BioSciences, Inc. has been selected for a late-breaking oral presentation at the Liver Meeting® 2025, highlighting its innovative gene editing capabilities [1] Company Summary - The company specializes in gene editing using its proprietary ARCUS® platform, focusing on developing in vivo gene editing therapies for diseases with high unmet medical needs [1] - The presentation will showcase new data from the PBGENE-HBV program, specifically from the first two cohorts of the Phase 1 ELIMINATE-B Trial [1]